A Phase 2 Study of Iadademstat in Combination With Paclitaxel in Relapsed or Refractory Small Cell Lung Cancer and Extrapulmonary High Grade Neuroendocrine Carcinomas

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Aug 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Iadademstat (Primary) ; Paclitaxel (Primary)
Indications Bladder cancer; Carcinoma; Neuroendocrine carcinoma; Prostate cancer; Small cell lung cancer
Focus Therapeutic Use
Acronyms NET

31 Jul 2024 According to an Oryzon media release, trial is being conducted in the U.S. under a collaborative clinical research agreement with the Fox Chase Cancer Center.
21 Mar 2024 Planned primary completion date changed from 5 Aug 2024 to 5 Aug 2025.
24 Oct 2023 Trial design presented at the 48th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com